

Karim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5300331/publications.pdf>

Version: 2024-02-01

138
papers

19,452
citations

23567

58
h-index

12597

132
g-index

145
all docs

145
docs citations

145
times ranked

14768
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial. <i>European Urology</i> , 2022, 81, 234-240.	1.9	12
2	Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial. <i>European Journal of Cancer</i> , 2022, 160, 61-71.	2.8	29
3	Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. <i>Nature Medicine</i> , 2022, 28, 144-153.	30.7	102
4	Estimation of Overall Survival with Subsequent Treatment Effect by Applying Inverse Probability of Censoring Weighting in the LATITUDE Study. <i>European Urology Open Science</i> , 2022, 36, 51-58.	0.4	2
5	Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study. <i>European Journal of Cancer</i> , 2022, 162, 56-64.	2.8	14
6	Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. <i>Future Oncology</i> , 2022, 18, 425-436.	2.4	28
7	Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 1132-1142.	27.0	341
8	Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. , 2022, 10, e004191.		23
9	Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2â€‰%â€‰â€‰2 factorial design. <i>Lancet, The</i> , 2022, 399, 1695-1707.	13.7	261
10	Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?. <i>Journal of Clinical Oncology</i> , 2022, 40, 3011-3014.	1.6	12
11	Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 825-832.	0.8	2
12	PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer. <i>Drugs</i> , 2022, 82, 719-733.	10.9	10
13	Reply to Ethan B. Ludmir, Zachary R. McGaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2020.07.032 . Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Cas. <i>European Urology</i> , 2021, 79, e12-e13.	1.9	0
14	Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. <i>Lancet Oncology, The</i> , 2021, 22, 402-410.	10.7	79
15	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. <i>European Journal of Cancer</i> , 2021, 146, 30-47.	2.8	81
16	Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies. <i>Oncologist</i> , 2021, 26, e1179-e1188.	3.7	2
17	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1563-1574.	1.6	108
18	Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?. <i>Cancer Treatment Reviews</i> , 2021, 97, 102204.	7.7	24

#	ARTICLE	IF	CITATIONS
19	Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021. <i>European Urology</i> , 2021, 80, 4-6.	1.9	6
20	KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2021, 17, 3291-3299.	2.4	22
21	Lutetium-177â€“PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 1091-1103.	27.0	1,042
22	Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. <i>Clinical Cancer Research</i> , 2021, 27, 6677-6686.	7.0	12
23	Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects. <i>European Journal of Cancer</i> , 2021, 159, 87-97.	2.8	6
24	Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. <i>European Journal of Cancer</i> , 2021, 159, 237-246.	2.8	6
25	An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer. <i>European Urology Oncology</i> , 2020, 3, 498-508.	5.4	27
26	Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials. <i>European Journal of Cancer</i> , 2020, 125, 142-152.	2.8	7
27	Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes. <i>JAMA Oncology</i> , 2020, 6, 206.	7.1	22
28	Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. <i>European Urology</i> , 2020, 78, 822-830.	1.9	99
29	Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. <i>Cancer Cell</i> , 2020, 38, 489-499.e3.	16.8	216
30	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2345-2357.	27.0	440
31	Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. <i>New England Journal of Medicine</i> , 2020, 383, 1040-1049.	27.0	225
32	Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. <i>Lancet Oncology</i> , The, 2020, 21, 1513-1525.	10.7	35
33	Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. <i>European Urology</i> , 2020, 78, 195-206.	1.9	192
34	Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa003.	2.9	1
35	Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2197-2206.	27.0	253
36	Event-Free Survival, a Prostate-Specific Antigenâ€“Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. <i>Journal of Clinical Oncology</i> , 2020, 38, 3032-3041.	1.6	37

#	ARTICLE	IF	CITATIONS
37	Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome. <i>European Journal of Cancer</i> , 2020, 129, 117-122.	2.8	12
38	Immunotherapy discontinuation – how, and when? Data from melanoma as a paradigm. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 707-715.	27.6	57
39	Olaparib for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2091-2102.	27.0	1,327
40	Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 444-451.	1.9	6
41	Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2487-2496.	7.0	273
42	Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097813.	3.2	11
43	Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2506-2518.	27.0	403
44	A Case of Heavily Pretreated Metastatic Germ Cell Tumor With Ongoing Long-term Complete Response After Gemcitabine Treatment. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e485-e487.	1.9	0
45	Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. <i>European Journal of Cancer</i> , 2019, 114, 107-116.	2.8	42
46	Fatigue and physical activity in cancer survivors: A cross-sectional population-based study. <i>Cancer Medicine</i> , 2019, 8, 2535-2544.	2.8	26
47	Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 686-700.	10.7	496
48	Overview of Systemic Therapy Augmenting Management of High-risk Localized Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 168-170.	3.1	1
49	Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 1235-1246.	27.0	621
50	Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. <i>European Urology</i> , 2019, 75, 88-99.	1.9	333
51	Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5017-5017.	1.6	2
52	Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT).. <i>Journal of Clinical Oncology</i> , 2019, 37, 141-141.	1.6	7
53	Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).. <i>Journal of Clinical Oncology</i> , 2019, 37, 142-142.	1.6	76
54	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	1.9	488

#	ARTICLE	IF	CITATIONS
55	Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. <i>European Urology</i> , 2018, 73, 696-703.	1.9	45
56	Reply to C. Ren et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 2354-2356.	1.6	0
57	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology</i> , The, 2018, 19, e696-e708.	10.7	90
58	Abiraterone in metastatic castration-resistant prostate cancer: Efficacy and safety in unselected patients. <i>Cancer Treatment and Research Communications</i> , 2018, 17, 37-42.	1.7	6
59	Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis. <i>European Journal of Cancer</i> , 2018, 103, 78-87.	2.8	71
60	Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 2465-2474.	27.0	782
61	Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 572-580.	1.6	187
62	Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 332-340.	1.9	64
63	PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3-3.	1.6	27
64	ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS383-TPS383.	1.6	18
65	Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre. <i>European Journal of Cancer</i> , 2017, 79, 185-192.	2.8	24
66	Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 352-360.	27.0	1,588
67	Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial. <i>European Urology Focus</i> , 2017, 3, 606-614.	3.1	18
68	Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2017, 76, 36-44.	2.8	64
69	Clinical News. <i>British Journal of Hospital Medicine</i> (London, England: 2005), 2017, 78, 368-371.	0.5	0
70	Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1081-e1088.	1.9	6
71	Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients. , 2017, 5, 31.		45
72	Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 168-171.	1.9	48

#	ARTICLE	IF	CITATIONS
73	Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 40-47.	1.6	577
74	Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial. <i>Cancer</i> , 2017, 123, 253-262.	4.1	42
75	Treatment of Castration-naive Metastatic Prostate Cancer. <i>European Urology Focus</i> , 2017, 3, 518-521.	3.1	2
76	Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol. <i>BMC Cancer</i> , 2017, 17, 549.	2.6	19
77	Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm. <i>Journal of Clinical Oncology</i> , 2017, 35, 3525-3528.	1.6	56
78	Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial—FIRSTANA. <i>Journal of Clinical Oncology</i> , 2017, 35, 3189-3197.	1.6	251
79	Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents. <i>Clinical Cancer Research</i> , 2016, 22, 5713-5721.	7.0	37
80	Nonfamilial Chronic Serum Alpha-Fetoprotein Increase in a Patient With Clinical Stage I Seminoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e91-e93.	1.9	1
81	Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors. <i>European Journal of Cancer</i> , 2016, 61, 44-51.	2.8	40
82	Biennial report on genitourinary cancers. <i>European Journal of Cancer</i> , 2016, 66, 125-130.	2.8	1
83	Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors. <i>Gynecologic Oncology</i> , 2016, 142, 452-457.	1.4	23
84	Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. <i>Journal of Clinical Oncology</i> , 2016, 34, 3005-3013.	1.6	202
85	Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. <i>European Journal of Cancer</i> , 2016, 69, 151-157.	2.8	31
86	Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study. <i>European Urology</i> , 2016, 69, 834-840.	1.9	49
87	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016, 34, 1402-1418.	1.6	1,089
88	Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1652-1659.	1.6	332
89	Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. <i>European Urology</i> , 2016, 70, 256-262.	1.9	355
90	Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 85-92.	0.8	28

#	ARTICLE	IF	CITATIONS
91	Programmed death-ligand 1 (PD-L1) expression in cured and not cured testicular and other germ cell tumors (GCT).. Journal of Clinical Oncology, 2016, 34, 485-485.	1.6	1
92	Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: a report from the PETRUS prospective study. Oncotarget, 2016, 7, 55069-55082.	1.8	33
93	Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 245-260.	1.6	45
94	Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncology, The, 2015, 16, 787-794.	10.7	206
95	Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5. Journal of Clinical Oncology, 2015, 33, 723-731.	1.6	127
96	Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. Journal of Clinical Oncology, 2015, 33, 1356-1363.	1.6	120
97	Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer. European Journal of Cancer, 2015, 51, 1946-1952.	2.8	63
98	Locoregional symptoms in patients with de novo metastatic prostate cancer: Morbidity, management, and disease outcome. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 202.e9-202.e17.	1.6	31
99	Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. European Urology, 2015, 68, 850-858.	1.9	74
100	Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?. European Urology, 2015, 68, 802-804.	1.9	0
101	Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. European Urology, 2015, 68, 196-204.	1.9	102
102	Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe. European Urology, 2015, 67, 904-912.	1.9	18
103	Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncology, The, 2015, 16, 509-521.	10.7	174
104	Docetaxel and prednisone with or without lenalidomide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncology, The, 2015, 16, 417-425.	10.7	137
105	High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. European Journal of Cancer, 2015, 51, 2570-2577.	2.8	91
106	Guidelines on Testicular Cancer: 2015 Update. European Urology, 2015, 68, 1054-1068.	1.9	538
107	ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. Expert Review of Anticancer Therapy, 2015, 15, 1007-1017.	2.4	63
108	Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. European Urology, 2015, 68, 228-235.	1.9	144

#	ARTICLE	IF	CITATIONS
109	The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2015, 33, 5000-5000.	1.6	25
110	Circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide post-chemotherapy (phase 3 AFFIRM study).. Journal of Clinical Oncology, 2015, 33, 5035-5035.	1.6	15
111	A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone.. Journal of Clinical Oncology, 2015, 33, TPS5072-TPS5072.	1.6	15
112	ARAMIS trial: Efficacy and safety phase 3 trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).. Journal of Clinical Oncology, 2015, 33, TPS5080-TPS5080.	1.6	0
113	Bone turnover marker (BTM) levels and clinical outcomes in advanced cancer patients (pts) treated with antiresorptive bone therapies.. Journal of Clinical Oncology, 2015, 33, e22236-e22236.	1.6	0
114	First prospective, open-label, phase 2 study of sipuleucel-T (sip-T) in European men with metastatic, castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2015, 33, e16015-e16015.	1.6	0
115	Disease burden and outcome in metastatic hormone sensitive prostate cancer (mHSPC).. Journal of Clinical Oncology, 2015, 33, 5052-5052.	1.6	0
116	One Size Does Not Fit All: Can We Choose the Best Sequence of Treatment in Asymptomatic Castration-resistant Prostate Cancer Patients?. European Urology, 2014, 66, 653-654.	1.9	1
117	Toxicities Following Treatment with Bisphosphonates and Receptor Activator of Nuclear Factor- κ B Ligand Inhibitors in Patients with Advanced Prostate Cancer. European Urology, 2014, 65, 278-286.	1.9	41
118	Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial Data. European Urology, 2014, 65, 713-720.	1.9	71
119	Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncology, The, 2014, 15, 1442-1450.	10.7	163
120	Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncology, The, 2014, 15, 1147-1156.	10.7	181
121	Compliance with guidelines and correlation with outcome in patients with advanced germ-cell tumours. European Journal of Cancer, 2014, 50, 1284-1290.	2.8	26
122	Patients'™ self-assessment versus investigators'™ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). European Journal of Cancer, 2014, 50, 953-962.	2.8	63
123	Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2014, 15, 700-712.	10.7	1,280
124	Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. European Journal of Cancer, 2014, 50, 1602-1609.	2.8	50
125	Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel. European Journal of Cancer, 2014, 50, 1617-1627.	2.8	133
126	A Risk-adapted Study of Cisplatin and Etoposide, with or Without Ifosfamide, in Patients with Metastatic Seminoma: Results of the GETUG S99 Multicenter Prospective Study. European Urology, 2014, 65, 381-386.	1.9	39

#	ARTICLE	IF	CITATIONS
127	Validation of a prognostic classification system for mediastinal nonseminomatous germ-cell tumors (MGCT).. Journal of Clinical Oncology, 2014, 32, 4562-4562.	1.6	1
128	Prostate cancer: ESMO Consensus Conference Guidelines 2012. Annals of Oncology, 2013, 24, 1141-1162.	1.2	137
129	Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2013, 31, 1740-1747.	1.6	184
130	Nonhormone Therapy for Metastatic Castration-Resistant Prostate Cancer: Chemotherapy, Bone-Targeted Treatments, and Others. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e161-e165.	3.8	2
131	Evaluation of circulating tumor cells (CTCs) enumeration and 18F-Choline positron emission tomography/computed tomography (FCH PET/CT) as early efficacy response biomarkers in metastatic castration-resistant prostate cancer (CRPC) patients (pts) treated with abiraterone acetate.. Journal of Clinical Oncology, 2012, 30, 63-63.	1.6	2
132	Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.. Journal of Clinical Oncology, 2012, 30, LBA1-LBA1.	1.6	66
133	Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2009, 27, 2429-2435.	1.6	157
134	Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates. Journal of Clinical Oncology, 2009, 27, 1564-1571.	1.6	491
135	New agents in metastatic prostate cancer. European Journal of Cancer, 2009, 45, 379-380.	2.8	4
136	Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncology, The, 2007, 8, 994-1000.	10.7	103
137	High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Research, 2004, 24, 2897-903.	1.1	23
138	Germ cell tumors in patients infected by the human immunodeficiency virus. Cancer, 2001, 92, 1460-1467.	4.1	18